首页> 外文期刊>Graefe's archive for clinical and experimental ophthalmology: Albrecht von Graefes Archiv fur klinische und experimentelle Opthalmologie >Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema
【24h】

Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema

机译:单独使用溴芬酸或单次玻璃体内注射贝伐单抗或曲安奈德治疗葡萄膜性黄斑水肿

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To evaluate the efficacy of bromfenac drops alone or with a single intravitreal injection of bevacizumab (IVB) or triamcinolone acetonide (IVTA) in the treatment of uveitic macular edema (UME). Design: Comparative case series. Study Participant: Sixty-seven eyes (of 55 patients) with UME that received either bromfenac drops alone (n = 34), IVB plus bromfenac (n = 21) or IVTA plus bromfenac (n = 12). Methods: Chart review of patients at the Massachusetts Eye Research and Surgery Institution (MERSI) was done. Eyes that received either bromfenac drops alone (Br), IVB plus bromfenac (IVB/Br) or IVTA plus bromfenac (IVTA/Br), with follow-up of up to 3 months, were included. Main Outcome Measure: Visual acuity. Results: There was no statistically significant effect seen in VA or CMT in the Br group, with 17 of 34 eyes (50 %) needing re-injection before 3 months of follow-up. Mean change in CMT at 4 weeks for the Br group was 5.06 μm. Compared to baseline, both the IVTA/Br and IVB/Br groups showed significant decrease in CMT and improvement in VA at 1 and 3 months follow-up. There was also a continuous decrease in CMT up to 3 months of follow-up with the IVTA/Br group, which was found to be significant in comparison with the IVB/Br group; this trend was not seen in the IVB/Br group at 3 months. The greatest mean change in CMT at 1 month was seen in the IVTA/Br group (154.33 ±178.22 μm), and this was statistically significant in comparison with the other groups (p = <0.0001). However, in terms of mean change in VA, there was no change in the Br group (0.01 ± 0.11 VA logMAR), and only 0.12 ± 0.19 and 0.15 ± 0.20 in the IVB/Br and IVTA/Br groups, respectively. Conclusion: IVB and IVTA are both effective in improving VA and decreasing CMT up to 3 months. Bromfenac is ineffective alone for UME treatment, but may have a synergistic effect with IVTA in reducing CMT up to 3 months of follow-up.
机译:目的:评估单独或单次玻璃体内注射贝伐单抗(IVB)或曲安奈德(IVTA)的溴芬酸滴眼液治疗葡萄膜黄斑水肿(UME)的疗效。设计:比较案例系列。研究对象:UME的67眼(55例患者)接受单独的溴芬酸滴剂(n = 34),IVB加溴芬酸(n = 21)或IVTA加溴芬酸(n = 12)。方法:对马萨诸塞州眼科研究和手术机构(MERSI)的患者进行了病历检查。包括单独接受溴芬酸滴剂(Br),IVB加溴芬酸(IVB / Br)或IVTA加溴芬酸(IVTA / Br)的眼,最长随访3个月。主要指标:视敏度。结果:Br组在VA或CMT中无统计学意义,在3个月的随访前34眼中有17眼(50%)需要再次注射。 Br组在4周时的平均CMT变化为5.06μm。与基线相比,IVTA / Br和IVB / Br组在随访1个月和3个月时均显示CMT显着降低和VA改善。 IVTA / Br组随访3个月后CMT也持续降低,与IVB / Br组相比有显着意义。 IVB / Br组在3个月时未见这种趋势。 IVTA / Br组在1个月时CMT的平均变化最大(154.33±178.22μm),与其他组相比,具有统计学意义(p = <0.0001)。但是,就VA的平均变化而言,Br组没有变化(0.01±0.11 VA logMAR),IVB / Br和IVTA / Br组分别只有0.12±0.19和0.15±0.20。结论:IVB和IVTA均可有效改善VA和降低CMT长达3个月。单独使用Bromfenac不能有效治疗UME,但在长达3个月的随访中,其可能与IVTA协同降低CMT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号